Gastric Cancer Palliative Care

Palliative care should be initiated early in the course of advanced gastric cancer , concurrent with active oncologic treatment. NCCN guidelines recommend that treatment of advanced gastric cancer be influenced by palliative care principles ^[11]B2a, and ASCO advocates for early palliative care integration to improve quality of life and potentially extend survival. Despite these recommendations, palliative care remains underutilized: in a nationwide Finnish study, only 21% of patients with advanced esophageal or gastric cancer had early specialist palliative care (SPC) contact (>30 days before death), while 79% had late or no SPC ^[15]B3b.

Evidence from Population Studies

Early SPC is associated with meaningful reductions in acute healthcare utilization. In the last month of life, patients with early SPC had fewer emergency department contacts (44% vs 60%, p<0.001) and fewer secondary care hospitalizations (32% vs 61%, p<0.001) compared to those with late/no SPC ^[15]B3b. Early SPC also increased access to hospital-at-home care (56% vs 6%) and SPC ward deaths (19% vs 4%) ^[15]B3b. Among hospitalized gastric cancer patients in the United States, palliative care consultation was associated with a $36,240 reduction in hospital charges (95% CI -$51,506 to -$20,974) and higher odds of do-not-resuscitate orders (aOR 4.77, 95% CI 3.99-5.70), without prolonging length of stay ^[13]B3b.

Disparities and Barriers

Access to palliative care is inequitable. Black patients had 32% lower odds of receiving palliative care compared to White patients (aOR 0.68, 95% CI 0.54-0.82) ^[13]B3b. Higher income, treatment at large urban teaching hospitals, and private insurance were associated with greater palliative care use ^[13]B3b. These disparities highlight the need for systematic efforts to ensure equitable access.

Special Populations: Older Adults

Gastric cancer predominantly affects older adults, yet clinical trials often exclude patients over 75. ESMO recommends geriatric assessment to determine functional age when initiating treatment ^[9]D5. In a real-world cohort, 77% of patients aged ≥75 did not receive palliative chemotherapy, with age cited as the reason in 25% ^[19]B3b. However, among those who did receive chemotherapy, outcomes were comparable to younger patients, underscoring that age alone should not be a barrier ^[19]B3b. Geriatric assessment can identify modifiable vulnerabilities, such as polypharmacy, malnutrition, and emotional distress, that, when addressed, may improve treatment tolerance and quality of life ^[16]C4.

Once palliative care is integrated, the focus shifts to systematic symptom management, discussed in the next section.

Pearl: Early specialist palliative care (>30 days before death) reduces emergency department visits and hospitalizations in the last month of life, yet fewer than one in four patients receive it ^[15]B3b.

Once palliative care is integrated, the focus shifts to relieving the burdens that define advanced disease: pain, bleeding, and progressive cachexia. The evidence for symptom-directed interventions in advanced gastric cancer is limited, and many recommendations are extrapolated from surgical series, but several targeted approaches are supported by the retrieved literature.

Pain Management

Pain in advanced gastric cancer is multifactorial, arising from tumor infiltration of the celiac plexus, peritoneal metastases, and bone involvement. Multimodal pharmacotherapy is the cornerstone, but the specific evidence for opioid regimens in this population is not reported in the retrieved studies. However, data from the perioperative setting suggest that opioid-sparing strategies are effective. In a retrospective cohort comparing robot-assisted minimally invasive gastrectomy (RAMIG) with open gastrectomy, RAMIG was associated with significantly reduced opioid consumption (p = 0.002) and lower pain scores during mobilization on postoperative days 5 and 7 (p = 0.011 and p = 0.002, respectively) and at rest on day 7 (p = 0.005) ^[35]B2b. Although these data derive from curative surgery, they support the principle that minimally invasive approaches reduce analgesic requirements. In a meta-analysis of six randomized controlled trials involving 1055 patients, robotic gastrectomy was associated with a shorter time to first flatus (WMD -0.28 days, 95% CI -0.48 to -0.07) and earlier liquid intake (WMD -0.3 days, 95% CI -0.42 to -0.19), reflecting faster recovery and potentially less pain ^[26]A1a.

Psychological intervention combined with enhanced nutritional support significantly improved pain management as measured by the Visual Analog Scale (VAS) in a randomized trial of 290 postoperative gastric cancer patients (p < 0.05) ^[24]A1b. This underscores the value of non-pharmacologic pain control even in the palliative setting.

For patients with advanced disease who are not surgical candidates, the retrieved evidence does not report specific analgesic doses or algorithms. The clinician should follow standard World Health Organization (WHO) analgesic ladder principles, with regular assessment and titration.

Bleeding

Acute upper gastrointestinal bleeding (UGIB) from gastric cancer carries high morbidity and mortality. Transcatheter arterial embolisation (TAE) is a viable option when endoscopic management fails or is not feasible. In a systematic review of seven retrospective studies, TAE for UGIB secondary to gastric cancer achieved a technical success rate of 94.9% and a clinical success rate of 72% (95% CI 66-79%) ^[37]B2a. The overall rebleeding rate was 11% (95% CI 3-18%), and major complications occurred in 2.4% of patients, including ischemic events and organ perforation. The 30-day mortality was 26.4%, primarily due to underlying disease progression rather than procedural complications ^[37]B2a. These findings support TAE as an effective and safe intervention, particularly for patients who are not candidates for curative surgery or are being considered for neoadjuvant therapy.

Severity of UGIB should be assessed clinically (hemodynamic status, hemoglobin drop), although the retrieved evidence does not report a specific risk stratification tool for this population. Antithrombotic medication use is a known risk factor for post-procedural bleeding: in a meta-analysis of 4868 patients undergoing endoscopic submucosal dissection (ESD) for early gastric cancer, antithrombotic use was associated with an odds ratio of 2.02 (95% CI 1.16-3.51) for postoperative bleeding ^[36]A1a. While this pertains to ESD, the principle of heightened bleeding risk with antithrombotic therapy likely applies to advanced disease as well.

In the GATSBY trial, second-line trastuzumab emtansine (2.4 mg/kg weekly) for HER2-positive advanced gastric cancer was associated with grade 3+ anemia in 26% of patients and serious bleeding events including upper gastrointestinal hemorrhage (4%), gastric hemorrhage (3%), and gastrointestinal hemorrhage (2%) ^[21]B2b. These rates highlight the need for vigilance for bleeding in patients receiving systemic therapy for advanced disease.

Other Symptoms

The retrieved evidence does not specifically address management of malignant ascites , dysphagia, or fistula in advanced gastric cancer. For dysphagia, palliative radiotherapy or stent placement may be considered, but supporting data from these references are absent. Lymphoedema and vaginal discharge were not reported in any of the included studies.

Controversies and Guideline Disagreement

No guideline-level disagreement was identified in the retrieved evidence, as the relevant clinical practice guidelines for palliative symptom management in gastric cancer were not included in the provided references.

Pearl: For acute upper gastrointestinal bleeding from gastric cancer, transcatheter arterial embolisation offers a 95% technical success rate and a 72% clinical success rate, with a 2.4% major complication rate, making it the preferred intervention when endoscopy fails or is not feasible ^[37]B2a.

Beyond physical symptom control, the psychosocial and spiritual dimensions of advanced gastric cancer profoundly affect patients and their families. This section addresses distress, existential suffering, and caregiver burden, core palliative-care domains that require systematic assessment and intervention.

Psychosocial and Spiritual Distress in Patients

Patients with advanced gastric cancer experience elevated rates of anxiety, depression, and loneliness. Cao & Zhou 2024 found that 210 gastrointestinal cancer patients post-resection had significantly higher scores for anxiety (HADS-A, P<0.001), depression (HADS-D, P<0.001), and loneliness (UCLA-LS, P<0.001) compared to 50 healthy controls, while spiritual well-being (FACIT-Sp) was significantly lower (P<0.001) ^[52]B3b. Attitudes toward death shifted toward fear and avoidance, with reduced neutral acceptance (P<0.001) and approach acceptance (P=0.010) ^[52]B3b.

Self-efficacy (SE) for coping with cancer is a modifiable factor. In 202 patients with advanced gastric cancer, SE for seeking medical information ranked highest, while SE for using spiritual coping ranked lowest ^[44]D5. SE for maintaining activity and independence, accepting cancer, maintaining a positive attitude, and making decisions each contributed significantly to quality of life (QoL) as measured by FACT-Ga and FACIT-Sp; SE for spiritual coping contributed specifically to spiritual well-being ^[44]D5. These findings support routine assessment of coping SE and targeted interventions to strengthen it.

Caregiver Burden: Psychological, Physical, and Economic

Family caregivers of patients with advanced gastric cancer bear substantial multidimensional burden. Psychological distress is common: a cross-sectional study of 207 caregivers of inpatients with gastric or colorectal cancer found that caregivers experienced both depression and high self-esteem, with attachment anxiety and avoidance influencing these outcomes through social support ^[42]B3b.

Physical consequences can be severe. A 71-year-old woman caring for her husband with advanced gastric cancer developed Wernicke encephalopathy after 5 months of reduced appetite; her consciousness returned to normal within 1 hour of intravenous thiamine 100 mg ^[51]C4. This case highlights that caregivers may develop thiamine deficiency from stress-related nutritional neglect, clinicians should assess both psychological and physical status in caregivers ^[51]C4.

Economic burden is substantial. In Taiwan, per-patient costs for advanced gastric cancer in 2013 were US$26,431 direct medical, US$4,669 direct non-medical, and US$5,758 morbidity costs, with mortality costs of US$145,990 per death; total national cost was US$423 million ^[46]D5. Across six countries, advanced gastroesophageal adenocarcinomas significantly reduced work productivity and caused income loss for both patients and caregivers ^[45]D5.

Knowledge and practice regarding postoperative dietary management among caregivers are moderate. In a study of 508 primary caregivers, mean knowledge score was 6.40±1.96 (53% of maximum), attitude score 32.87±2.81 (82% positive), and practice score 33.24±6.38 (66% proactive) ^[43]B3b. Notably, knowledge was negatively correlated with practice (r=-0.228, P<0.001), while attitude positively correlated with practice (r=0.117, P=0.008) ^[43]B3b. Higher attitude scores were independently associated with better practice (OR 1.360, 95% CI 1.223-1.513, P<0.001), whereas longer caregiving duration (>3 months) was associated with lower practice scores ^[43]B3b.

Dyadic Interdependence

Quality of life is interdependent between patients and caregivers. In 353 patient-caregiver dyads, QoL was positively correlated (r=0.287, P<0.001) ^[50]D5. Actor-partner interdependence modeling revealed that caregivers' health literacy and positive coping positively predicted patients' QoL, while patients' positive coping positively predicted caregivers' QoL ^[50]D5. Communication patterns also matter: qualitative analysis of 16 patient-spouse dyads identified positive, negative, and protective-concealment communication styles that influence psychological adaptation and relationship intimacy ^[48]D5.

Nutritional challenges are a source of distress for both parties. Qualitative interviews with 20 participants (patients, caregivers, physicians, nurses) identified themes including eating as an unpleasant experience ("a feeling like hyperemesis gravidarum"), flexibility while adhering to diet, and nutrition with distress, patients' sense of being an extra burden and caregivers' provision of nutrition with suffering ^[47]D5.

Interventions

A family-cohesion-centered frailty intervention based on the Satir Family Therapy Model showed significant benefits in a non-randomized controlled trial of 79 older gastric cancer patients (age ≥60) and their family caregivers ^[41]A1b. The experimental group received five weekly therapist-led sessions focused on enhancing health literacy, emotional cognition, effective communication, and positive coping. Compared to standard care, the intervention produced significant group-by-time interactions for frailty (T1: β=-0.646, P=0.026; T2: β=-0.859, P=0.034), family cohesion (T1: β=1.513, P=0.001; T2: β=3.194, P<0.001), self-efficacy (T1: β=1.699, P=0.028; T2: β=4.212, P<0.001), anxiety (T1: β=-0.672, P=0.043; T2: β=-0.762, P=0.007), depression (T1: β=-0.633, P=0.038; T2: β=-0.812, P=0.003), and quality of life at T2 (β=4.843, P<0.001) ^[41]A1b. No adverse events were reported ^[41]A1b. Moderation analysis suggested greater benefits for older patients and those with less advanced TNM stage ^[41]A1b.

Spiritual Care

Spiritual well-being is compromised in this population. Patients with gastrointestinal cancer after resection had significantly lower FACIT-Sp scores than controls ^[52]B3b. Given that self-efficacy for spiritual coping is the lowest domain of coping SE ^[44]D5, clinicians should actively explore spiritual and existential concerns, facilitate meaning-making, and provide or refer for chaplaincy or counseling services.

Pearl: For caregivers, assess nutritional intake and consider thiamine levels if appetite has been poor for weeks, Wernicke encephalopathy can develop rapidly and is reversible with IV thiamine ^[51]C4. For patients, the lowest self-efficacy domain is spiritual coping, not medical information-seeking; assessing and supporting spiritual coping may improve overall well-being ^[44]D5.

Building on the multidisciplinary approach to psychosocial and spiritual care, clinicians must also address the physical complications of advanced gastric cancer through targeted palliative procedures. The most common symptomatic indications, bleeding, gastric outlet obstruction (GOO), and biliary obstruction, each require a distinct procedural strategy.

Palliative Radiotherapy for Bleeding

Palliative radiotherapy (RT) is effective for tumor bleeding. A meta-analysis of 11 studies reported a pooled bleeding response rate of 77% (95% CI 0.73-0.81) ^[55]B2a. The response correlates with biologically effective dose (BED): rates were 79% for BED Gy10 ≥40, 79% for BED 30-39, and for BED <30 (p=0.0001) ^[55]B2a. Another systematic review found a pooled bleeding response of 74%, with no significant difference between high and low BED (p=0.39) ^[56]B2a. Grade 3-4 toxicity occurred in up to 15% with RT alone and up to 25% with chemoradiotherapy ^[56]B2a. In the multicenter JROSG 17-3 study, the per-protocol bleeding response rate reached 90% at 8 weeks ^[60]B3b. A retrospective study of 120 courses reported a hemostasis rate of 59.6%; median overall survival was 3.7 months, and responders survived 2.5 months longer than non-responders (p<0.0001) ^[58]C4. Higher BED was independently associated with hemostasis (p=0.006) ^[58]C4. Severe adverse events (grade ≥3) occurred in 5% ^[58]C4. RT also improves pain, dyspnea, and distress scores over 8 weeks, regardless of baseline Palliative Prognostic Index ^[57]B3b.

Palliative Radiotherapy for Obstruction and Pain

RT also palliates obstructive symptoms and pain. Pooled response rates are 68% for obstruction and 67% for pain ^[56]B2a. In a retrospective series, response rates were 88.8% for bleeding and 80% for obstruction, with median event-free survival of approximately 103 days ^[63]C4. Low BED regimens appear adequate for palliation, though the optimal dose-fractionation remains uncertain ^[56]B2a.

Endoscopic Stenting for Gastric Outlet Obstruction

Self-expanding metallic stent (SEMS) placement provides rapid symptom relief for GOO. Technical success exceeds 96% and clinical success 79-97% across studies ^{[54]A1b[61]B3b[66]C4}. Stent design influences long-term patency. In a multicenter RCT, a covered SEMS with anti-migration design (WAVE stent) showed comparable 8-week patency to uncovered SEMS (72.5% vs 62.7%, p=0.290) but significantly superior 16-week patency (68.6% vs 41.2%, p=0.005) ^[54]A1b. The WAVE stent reduced restenosis from 37.8% to 7.1% (p=0.001) without increasing migration (9.5% vs 5.4%, p=0.491) ^[54]A1b. Independent predictors of 16-week patency included WAVE stent placement (HR 0.51) and post-stent chemotherapy ^[54]A1b. Peritoneal carcinomatosis (PC) predicts lower clinical success: 66.7% with PC vs 88.6% without (p=0.036) ^[66]C4. Other predictors of clinical failure include need for narcotics after stenting, PC, and poor performance status ECOG 2-3 ^[14]B3b.

Stenting versus Gastrojejunostomy

Both SEMS and surgical gastrojejunostomy (GJJ) are effective for GOO but differ in outcomes. A meta-analysis of 9 studies found that SEMS provided shorter procedure time (WMD -80.9 min), faster oral intake (WMD -3.5 days), and shorter hospital stay (WMD -7.7 days), but GJJ had lower rates of major complications (OR 6.91 for SEMS), re-obstruction (OR 7.75), and reintervention (OR 6.27), and longer patency (by 167 days) and survival (by 103 days) ^[53]B2a. Propensity-matched analyses confirm that SEMS yields faster symptom relief and shorter hospitalization, while GJJ provides longer symptom-free duration, better nutritional status, and lower recurrence ^[67]B3b. In one study, GJJ was associated with longer overall survival (393 vs 129 days) and lower reintervention risk ^[65]B3b. However, another matched analysis showed comparable survival after matching (7.8 vs 4.0 months, p=0.38) with lower postoperative complications in the stent group (3% vs 21%) ^[61]B3b. Stent placement is preferred for patients with limited life expectancy or poor performance status; GJJ should be considered for those with good performance status and longer expected survival ^{[53]B2a[67]B3b}.

Palliative Biliary Stenting

Malignant biliary obstruction is managed with endoscopic or percutaneous stent placement. Biliary stenting effectively reduces hyperbilirubinemia in 96% of patients, but infectious complications occur in 28% (most commonly cholangitis) ^[59]C4. Median overall survival after biliary stenting is 20.3 weeks ^[59]C4. A double-stent system with long duodenal extension had a median patency of 83 days and median survival of 92 days, with stent occlusion due to food impaction in 23.8% ^[64]C4.

When procedural interventions are no longer effective or appropriate, the focus transitions to comprehensive end-of-life care and hospice support, as discussed in the next section.

Pearl: For GOO, choose SEMS when life expectancy is short or performance status poor; choose gastrojejunostomy for patients with good performance status and longer expected survival, as it provides superior long-term patency, lower reintervention rates, and potentially better survival ^{[53]B2a[65]B3b[67]B3b}.

Once palliative procedures have addressed obstructive and bleeding complications, the clinical focus shifts to comprehensive end-of-life care. This encompasses hospice eligibility assessment, advance care planning, and management of terminal symptoms. Despite the high symptom burden, specialist palliative care (SPC) remains underutilized in advanced gastric cancer .

Hospice Utilization and Disparities

Only 32% of patients with advanced esophageal or gastric cancer in a nationwide Finnish cohort had any SPC contact; only 21% received early SPC (contact >30 days before death) ^[15]B3b. In U.S. hospitalizations ending in death from gastric cancer, 57.6% received palliative care ^[13]B3b. Early SPC was associated with fewer emergency department contacts (44% vs. 60%, p < 0.001) and fewer secondary care hospitalizations (32% vs. 61%, p < 0.001) in the last month of life, and more patients died at home (19% vs. 11%, p = 0.011) ^[15]B3b.

Significant disparities persist. Black patients had 32% lower odds of receiving palliative care than White patients (aOR 0.68, 95% CI 0.54-0.82) ^[13]B3b. Higher income, large hospitals, urban teaching hospitals, and private insurance were associated with greater palliative care use ^[13]B3b. Among 815,780 upper gastrointestinal cancer decedents, most died at home (55.7%), followed by inpatient hospital (24.8%) and hospice (9.0%) ^[73]D5. Black race (OR 0.41, 95% CI 0.40-0.42) and high social vulnerability (OR 0.64, 95% CI 0.63-0.65) were independently associated with lower odds of dying at home compared with inpatient hospital ^[73]D5.

Advance Care Planning and Communication

Advance care planning (ACP) is essential but often suboptimally executed. In a simulation study of a 78-year-old man with metastatic gastric cancer and hypoxia, physicians demonstrated low skill at handling emotions (mean score 0.7 out of 6) and only moderate skill at discussing end-of-life goals (mean 7.4 out of 16) ^[77]D5. Skill at discussing end-of-life goals was associated with initiation of palliative care (p = 0.04) ^[77]D5. Provision of personalized prognostic information increased physicians' intentions to communicate prognosis (P < 0.001, η² = 0.38), an effect moderated by higher perceived credibility of prognostic models, higher numeracy, and lower perceived patient distress ^[76]D5.

Norms vary across institutions. In a simulation comparing two academic medical centers, the low-intensity ICU-use center had routine universal code status discussions, whereas the high-intensity center had norms of oncologists avoiding such discussions, suggesting that institutional ACP norms influence end-of-life decision-making ^[74]D5. Family override of do-not-resuscitate orders is a recurring ethical challenge, exemplified by cases where family members demanded aggressive measures despite prior patient agreement ^[72]C4.

Terminal Symptom Management and Treatment Decisions

Chemotherapy use declines as death approaches (35.9% in the third month before death to 7.9% in the final week), but artificial nutrition paradoxically increases from 9.6% to 16.0% in the same period, despite guidelines recommending limitation in contexts of limited life expectancy ^[75]D5. Gastric cancer patients were more likely to receive chemotherapy in the last week of life (aOR 1.35, 95% CI 1.17-1.56) but less likely to receive artificial nutrition (aOR 0.80, 95% CI 0.73-0.88) compared with esophageal cancer patients ^[75]D5. Use of chemotherapy in the last week varied from 1.6% in rural hospitals to 11.2% in comprehensive cancer centers ^[75]D5.

Palliative care during terminal hospitalizations was associated with a $36,240 reduction in hospital charges (95% CI -$51,506 to -$20,974, p < 0.01) and higher odds of do-not-resuscitate status (aOR 4.77, 95% CI 3.99-5.70), with lower odds of CPR, mechanical ventilation, transfusion, and vasopressor use, and no significant difference in length of stay ^[13]B3b.

Pearl: Early specialist palliative care (contact >30 days before death) reduces emergency visits and hospitalizations and increases the chance of dying at home; clinicians should initiate SPC referral proactively in advanced gastric cancer, especially given that only one in five patients currently receives timely palliative care ^[15]B3b.

Part of the Gastric Cancer family. Cross-cutting management is split across dedicated child pages:

• Gastric Cancer , diagnostic page (definition, epidemiology, staging, biomarkers, prognosis)
• Gastric Cancer Surgical Management , operations by stage, fertility-sparing options, sentinel node mapping, adjuvant triggers (Sedlis / Peters)
• Gastric Cancer Radiation Management , EBRT + image-guided brachytherapy + concurrent chemoradiation, dose / fractionation, OAR constraints
• Gastric Cancer Systemic Therapy , concurrent / adjuvant / metastatic chemotherapy, targeted therapy, immune checkpoint inhibitors
• Gastric Cancer Surveillance and Follow-up , post-treatment surveillance schedule, late toxicity, survivorship, patient counselling
• Gastric Cancer Recurrent and Metastatic Disease , local-regional salvage, distant metastatic systemic therapy, oligometastatic disease

Pearl: Use these links to hop between management modalities; the parent Gastric Cancer page carries diagnosis + staging that informs every decision here.